61 related articles for article (PubMed ID: 16083587)
1. [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast].
Huang P; Wang Y; Chi ZY; Yang ZY; Ni J; Yang WJ; Wang RD; Bai JZ
Zhonghua Wai Ke Za Zhi; 2005 Jun; 43(12):812-6. PubMed ID: 16083587
[TBL] [Abstract][Full Text] [Related]
2. [Effects of recombinant human osteoprotegerin and recombinant RANK protein on the differentiation of osteoclast precursors].
Xiong Q; Zhang LC; Zhang LH; Yao Q; Tang P
Zhongguo Gu Shang; 2013 Apr; 26(4):324-7. PubMed ID: 23844495
[TBL] [Abstract][Full Text] [Related]
3. [Effect of recombinant human osteoprotegerin on osteoclasts stimulated by polyethylene particles].
Zhang H; Huang C; Chen S
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Aug; 22(8):979-83. PubMed ID: 18773818
[TBL] [Abstract][Full Text] [Related]
4. Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo.
Xiong Q; Xin L; Zhang L; Tang P; Zhang L
Mol Med Rep; 2015 Jul; 12(1):631-8. PubMed ID: 25738879
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
6. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
7. Effects of alendronate on osteoclast formation and activity in vitro.
Martins CA; Leyhausen G; Volk J; Geurtsen W
J Endod; 2015 Jan; 41(1):45-9. PubMed ID: 25442070
[TBL] [Abstract][Full Text] [Related]
8. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
10. [Effects of L-threonate on bone resorption by osteoclasts in vitro].
He JH; Tong NW; Li HQ; Wu J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):225-8. PubMed ID: 15807273
[TBL] [Abstract][Full Text] [Related]
11. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
Itoh N; Kasai H; Ariyoshi W; Harada E; Yokota M; Nishihara T
J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
[TBL] [Abstract][Full Text] [Related]
14. Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts.
Tanaka H; Tanabe N; Shoji M; Suzuki N; Katono T; Sato S; Motohashi M; Maeno M
Life Sci; 2006 Mar; 78(15):1733-40. PubMed ID: 16266722
[TBL] [Abstract][Full Text] [Related]
15. [Effects of the osteoclast in pathogenesis of multiple myeloma].
Zhang JH; Fu JX; Zhang XH; Sun Y
Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):323-6. PubMed ID: 17877161
[TBL] [Abstract][Full Text] [Related]
16. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis.
Wu Y; Liu J; Feng X; Yang P; Xu X; Hsu HC; Mountz JD
Arthritis Rheum; 2005 Oct; 52(10):3257-68. PubMed ID: 16200600
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats.
Miyaji Y; Kurihara A; Kamiyama E; Shiiki T; Kawai K; Okazaki O
Xenobiotica; 2009 Feb; 39(2):113-24. PubMed ID: 19255937
[TBL] [Abstract][Full Text] [Related]
18. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
19. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro.
Huang J; Yuan L; Wang X; Zhang TL; Wang K
Life Sci; 2007 Aug; 81(10):832-40. PubMed ID: 17764702
[TBL] [Abstract][Full Text] [Related]
20. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.
Thompson K; Rogers MJ; Coxon FP; Crockett JC
Mol Pharmacol; 2006 May; 69(5):1624-32. PubMed ID: 16501031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
